Viewpoint Press Release Archive
In 2023 Viewpoint Molecular Targeting merged with Isoray. Access the archived Press Releases from Viewpoint Molecular Targeting.
Viewpoint Molecular Targeting® Appoints Thijs Spoor as Chief Executive Officer
Established leader with nearly 30 years of combined executive, broad management and capital markets expertise across healthcare and medical device industries CORALVILLE, IA / February 22, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, announced...
Viewpoint Molecular Targeting® to Present at the Virtual Investor 2022 Top Picks Conference
– Live video webcast presentation on Tuesday, January 25th at 11:00 AM ET CORALVILLE, IA / January 20, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Frances L. Johnson, MD,...
Viewpoint Molecular Targeting® to Present at the H.C. Wainwright BioConnect Conference
CORALVILLE, IA / January 5, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Frances L. Johnson MD, Chief Executive Officer and Co-Founder of Viewpoint, will present at the virtual H.C....
Viewpoint Molecular Targeting® Presents Preclinical Data from VMT- 𝛼 -NET, Theranostic in Development for the Treatment and Diagnosis of Neuroendocrine Tumors, at the Pacifichem 2021 Congress
Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors Preclinical data of VMT– alpha-NET demonstrated to significantly improve cell binding, tumor accumulation/retention and renal clearance of an SSTN analog VMT– alpha-NET currently in a Phase 1 imaging study to be followed by Phase 1/2a therapy study for the...
Viewpoint Molecular Targeting® Enters Agreement with UK-Based National Nuclear Laboratory, Ltd. to Advance Development of Targeted Alpha Therapy for Cancer
Viewpoint is focused on solidifying a global [212Pb] supply strategy through relationship building from research through commercialization Agreement significantly expands Company’s network of researchers and clinicians in the UK and Europe CORALVILLE, IA / November 16, 2021 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company...
Viewpoint Molecular Targeting® to Present at the Virtual Investor Roundtable Event
Live moderated video webcast discussion among members of Viewpoint Management and Thought Leaders Oliver Sartor MD, Geoffrey B. Johnson MD, PhD, Vikas Prasad MD, on Thursday, November 18th at 1:00 PM ET CORALVILLE, IA / November 11, 2021 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical...
Viewpoint Molecular Targeting® Announces Publication of Preclinical Data of VMT01 in Peer-Reviewed Journal, “Cancers”
Viewpoint advancing new, proprietary class of personalized 212 Pb-based alpha-particle radiopharmaceuticals to transform the treatment landscape of radiotherapies for cancer Positive preclinical data have demonstrated that a single dose of [212 Pb]VMT01 has significantly arrested melanoma tumor growth and extended survival The combination of [212 Pb]VMT01 and immune checkpoint...
Viewpoint Molecular Targeting® Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors
VMT–NET Phase 1 imaging study to be followed by Phase 1/2a therapy study for the treatment of neuroendocrine tumors being conducted at the University of Iowa Preclinical efficacy results demonstrated VMT–NET to significantly inhibit tumor growth and improve survival compared to untreated controls VMT–NET imaging study provisional results expected...
Viewpoint Molecular Targeting® to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”] CORALVILLE, IA / September 8, 2021 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Frances L. Johnson MD, Chief Executive Officer and Co-Founder of...
Viewpoint Molecular Targeting® Appoints Amos Hedt as Chief Business Strategy Officer
Well-established research professional with expertise in early-stage pharmaceutical and biotechnology drug development Company driving advancement of proprietary image-guided alpha-particle radiotherapies designed to optimize treatment, improve efficacy, and minimize the toxicity associated with many other cancer drugs CORALVILLE, IA / July 14, 2021 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or...
Viewpoint Molecular Targeting® Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program
Companies forge relationship to accelerate peptide drug discovery for next-generation radiopharmaceuticals Pepscan brings proprietary world-leading peptide drug discovery expertise and technologies Viewpoint to apply expertise in radiopharmaceuticals, chelation technologies and bioconjugate chemistry to accelerate the pace of discovery to clinic-ready radiopharmaceuticals CORALVILLE, IA / July 7, 2021 / Viewpoint...
Viewpoint Molecular Targeting™ Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting
– Presented data highlights the performance of Viewpoint’s chelation technology – Coralville, IA, June 15, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Michael K. Schultz PhD, Chief Science...
